Guided Therapeutics Targeting Large Cervical Cancer Screening Markets With Luviva® Advanced Cervical Scan With New Single-Patient-Use Disposable

Up to two billion women in the developing world could benefit from quick, painless, high-tech scan

NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHPD), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that the company is now shipping a new screening version of its single-use disposable Cervical Guide designed to make the product accessible to the approximately 2.0 billion women at risk for cervical cancer in the developing world.

“Our new screening Cervical Guide, one of which is used with each patient, is designed to cost less to ship, take up less storage space and produce less waste”

Screening for cervical cancer offers one of the largest opportunities available in diagnostic medicine. A woman becomes “at risk” for cervical cancer after becoming sexually active. Cervical cancer is linked to a sexually transmitted disease — human papillomavirus (HPV). In the developing world there are approximately 2.0 billion women aged 15 and older who are potentially eligible for screening with LuViva.

Screening for cervical cancer in the developing world also presents the opportunity to work with governments. Partnering with governments can provide immediate access to large numbers of lives covered under national or regional governmental healthcare programs.

“Our new screening Cervical Guide, one of which is used with each patient, is designed to cost less to ship, take up less storage space and produce less waste,” said Gene Cartwright, CEO and president of Guided Therapeutics, Inc. “We will be rolling out the new Cervical Guides in the coming months in countries where we are actively working with distributors to implement government-sponsored screening programs — Turkey, Bangladesh, Indonesia, Kenya and Nigeria. The number of screening candidates in those countries is approximately 246 million and represents three of the 10 most populous countries in the world.”

Worldwide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. Including the developed countries, there are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide.

Internationally, the company has regulatory approval to sell LuViva in Europe upon receipt of our Edition 3CE Mark in January 2014. LuViva has marketing approval from Health Canada, COFEPRIS in Mexico, Ministry of Health in Kenya and the Singapore Health Sciences Authority.

About LuViva^® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva^® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHPD) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva^® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and “Early detection, better outcomes” are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in our prior financings and our ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent filings.